関: hemorrhagic fever

WordNet

a rise in the temperature of the body; frequently a symptom of infection (同)febrility, febricity, pyrexia, feverishness
intense nervous anticipation; "in a fever of resentment"
highly excited; "a fevered imagination"

PrepTutorEJDIC

〈U〉《しばしばa fever》(身体の異常な)『熱』,発熱 / 〈U〉『熱病』 / 〈U〉〈C〉(…に対する)『興奮』,熱狂《+『for』+『名』》
(比較変化なし)《名詞の前にのみ用いて》熱のある,熱病にかかった / 熱にうかされたような,興奮した / (憎しみなどが)異常に強い

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/03/31 10:34:07」(JST)

wiki en

[Wiki en表示]

"VHFs" redirects here. For the former military installation in Virginia, see Vint Hill Farms Station.

The viral hemorrhagic (or haemorrhagic) fevers (VHFs) are a diverse group of animal and human illnesses that may be caused by five distinct families of RNA viruses: the families Arenaviridae, Filoviridae, Bunyaviridae, Flaviviridae, and Rhabdoviridae. All types of VHF are characterized by fever and bleeding disorders and all can progress to high fever, shock and death in many cases. Some of the VHF agents cause relatively mild illnesses, such as the Scandinavian nephropathia epidemica, while others, such as the African Ebola virus, can cause severe, life-threatening disease.

Etiologic agents[edit]

Five families of RNA viruses have been recognised as being able to cause this syndrome.

The family Arenaviridae include the viruses responsible for Lassa fever, Lujo virus, Argentine, Bolivian, Brazilian and Venezuelan hemorrhagic fevers.
The family Bunyaviridae include the members of the Hantavirus genus that cause hemorrhagic fever with renal syndrome (HFRS), the Crimean-Congo hemorrhagic fever (CCHF) virus from the Nairovirus genus, Garissa virus and Ilesha virus from the Orthobunyavirus and the Rift Valley fever (RVF) virus from the Phlebovirus genus.
The family Filoviridae include Ebola virus and Marburg virus.
The family Flaviviridae include dengue, yellow fever, and two viruses in the tick-borne encephalitis group that cause VHF: Omsk hemorrhagic fever virus and Kyasanur Forest disease virus.
In September 2012 scientists writing in the journal PLOS Pathogens reported the isolation of a member of the Rhabdoviridae responsible for 2 fatal and 2 non-fatal cases of hemorrhagic fever in the Bas-Congo district of the Democratic Republic of Congo. The non-fatal cases occurred in healthcare workers involved in the treatment of the other two, suggesting the possibility of person-to-person transmission.^[1] This virus appears to be unrelated to previously known Rhabdoviruses.

Clinical and treatment aspects[edit]

Signs and symptoms of VHFs include (by definition) fever and bleeding diathesis. Manifestations of VHF often also include flushing of the face and chest, petechiae, frank bleeding, edema, hypotension, and shock. Malaise, myalgias, headache, vomiting, and diarrhea occur frequently. Definitive diagnosis is usually made at a reference laboratory with advanced biocontainment capabilities.

The findings of laboratory investigation vary somewhat between the viruses but in general there is a decrease in the total white cell count particularly the lymphocytes, a decrease in the platelet count, an increase in the serum liver enzymes as well as increase in both the prothrombin (PT) and activated partial thromboplastin times (PTT). The hematocrit may be elevated. The serum urea and creatine may be raised but this is dependent on the hydration status of the patient. The bleeding time tends to be prolonged.

Medical management of VHF patients may require intensive supportive care. Antiviral therapy with intravenous ribavirin may be useful in Bunyaviridae and Arenaviridae infections (specifically Lassa fever, RVF, CCHF, and HFRS due to Old World Hantavirus infection) and can be used only under an experimental protocol as investigational new drug (IND) approved by the U.S. Food and Drug Administration (FDA). Interferon may be effective in Argentine or Bolivian hemorrhagic fevers (also available only as IND). Experimental vaccines for other VHFs are not readily available.

Prophylactic (preventive) ribavirin may be effective for some bunyavirus and arenavirus infections (again, available only as IND).

VHF isolation guidelines dictate that all VHF patients (with the exception of dengue patients) should be cared for using strict contact precautions, including hand hygiene, double gloves, gowns, shoe and leg coverings, and faceshield or goggles. Lassa, CCHF, Ebola, and Marburg viruses may be particularly prone to nosocomial (hospital-based) spread. Airborne precautions should be utilized including, at a minimum, a fit-tested, HEPA filter-equipped respirator (such as an N-95 mask), a battery-powered, air-purifying respirator, or a positive pressure supplied air respirator to be worn by personnel coming within six feet of a VHF patient. Multiple patients should be cohorted (sequestered) to a separate building or a ward with an isolated air-handling system. Environmental decontamination is typically accomplished with hypochlorite or phenolic disinfectants.^[2]

Pathophysiology[edit]

The diversity of clinical features seen among the VHF infections probably originates from varying mechanisms of pathogenesis. An immunopathogenic mechanism, for example, has been identified for dengue hemorrhagic fever, which usually occurs among patients previously infected with a heterologous dengue serotype. An influential theory explaining this phenomenon is called “antibody-dependent enhancement.” In contrast, disseminated intravascular coagulation (DIC) is thought to underlie the hemorrhagic features of Rift Valley, Marburg and Ebola fevers. In most VHFs, however, the etiology of the coagulopathy is most likely multifactorial (e.g., hepatic damage, consumptive coagulopathy, primary marrow dysfunction, etc.).

The reasons for variation among patients infected with the same virus are unknown but stem from a complex system of virus-host interactions. Moreover, why some infected persons develop full-blown VHF while others do not also remains an unresolved issue. Virulence of the infecting agent clearly plays an important role. The “VHF syndrome” (capillary leak, bleeding diathesis and hemodynamic compromise leading to shock) occurs in a majority of patients manifesting disease from filoviruses, CCHF, and the South American hemorrhagic fever viruses, while it occurs in a small minority of patients with dengue, RVF and Lassa fever.

Biowarfare/bioterrorism potential[edit]

The VHF viruses are spread in a variety of ways. Some may be transmitted to humans through a respiratory route. Although evidence for a history of “weaponization” (development into a biological weapon) does not exist for many of these viruses, all are considered by military medical planners to have a potential for aerosol dissemination, weaponization, or likelihood for confusion with similar agents that might be weaponized.^[3]^[4]

Notable VHF outbreaks[edit]

Cocoliztli in Mexico 1545.^[5]^[6]^[7]^[8]^[9]
The Great Yellow Fever Epidemic of 1793 in Philadelphia, PA USA. Nearly 10% of the population of 50,000 succumbed to the disease.
Mékambo in Gabon is the site of several outbreaks of Ebola virus disease.
Orientale Province, Democratic Republic of the Congo villages of Durba and Watsa were the epicenter of the 1998–2000 outbreak of Marburg virus disease.
Uíge Province in Angola is the site of world's worst hemorrhagic fever epidemic, which occurred in 2005.
A VHF outbreak in the village of Mweka, Democratic Republic of the Congo (DRC) that started in August 2007, and that has killed 103 people (100 adults and three children), has been shown to be caused (at least partially) by Ebola virus.
A viral hemorrhagic fever is a possible cause of the Plague of Athens during the Peloponnesian War.^[10]
The initial, and currently only, outbreak of Lujo virus in September–October 2008 left 4/5 patients dead.^[11]

References[edit]

^ Grard G, Fair JN, Lee D, et al. (September). "A novel rhabdovirus associated with acute hemorrhagic fever in central Africa". PLoS Pathog. 8 (9): e1002924. doi:10.1371/journal.ppat.1002924. PMC 3460624. PMID 23028323. Check date values in: |date= (help)
^ Woods, Lt Col Jon B., ed. (2005). USAMRIID’s Medical Management of Biological Casualties Handbook (PDF) (6th ed.). Fort Detrick MA: U.S. Army Medical Institute of Infectious Diseases. pp. 143–4.
^ Woods 2005, p. 145
^ Peters, C. (2000). "Are Hemorrhagic Fever Viruses Practical Agents for Biological Terrorism?". In Scheld, W. M.; Craig, W. A.; Hughes, J. M. Emerging Infections 4. Washington, DC: ASM Press. pp. 201–209. ISBN 1555811973.
^ Was the Huey Cocoliztli a Haemorrhagic Fever?
^ Indigenous Hemorrhagic Fever and The Spanish Conquest
^ Acuna-Soto R, Romero LC, Maguire JH (June 2000). "Large Epidemics of Hemorrhagic Fevers in Mexico 1545–1815" (PDF). Am J Trop Med Hyg 62 (6): 733–9. PMID 11304065.
^ Acuna-Soto R, Stahle DW, Cleaveland MK, Therrell MD (April). "Megadrought and megadeath in 16th century Mexico". Emerging Infect. Dis. 8 (4): 360–2. doi:10.3201/eid0804.010175. PMC 2730237. PMID 11971767. Check date values in: |date= (help)
^ Epidemics in New Spain
^ Olson PE, Hames CS, Benenson AS, Genovese EN (1996). "The Thucydides syndrome: Ebola déjà vu? (or Ebola reemergent?)". Emerging Infect. Dis. 2 (2): 155–6. doi:10.3201/eid0202.960220. PMC 2639821. PMID 8964060.
^ Briese, T.; Paweska, J.T.; McMullan, L.K.; Hutchison, S.K.; Street, C.; Palacios, G.; Khristova, M.L.; Weyer, J.; Swanepoel, R.; Engholm, M.; Nichol, S.T.; Lipkin, W.I. (2009). "Genetic Detection and Characterization of Lujo Virus, a New Hemorrhagic Fever–Associated Arenavirus from Southern Africa". PLoS Pathog 5 (5): e1000455. doi:10.1371/journal.ppat.1000455. PMC 2680969. PMID 19478873.

Health Protection Agency
This article includes information that originally came from US Government publications and websites and is in the public domain.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ハンタウイルス感染による腎疾患（腎症候性出血熱） renal involvement with hantavirus infection hemorrhagic fever with renal syndrome
2. エボラ出血熱およびマールブルグ出血熱の診断および治療 diagnosis and treatment of ebola and marburg hemorrhagic fever
3. 血小板減少症候群ウイルスによる重度の発熱 severe fever with thrombocytopenia syndrome virus
4. デング熱ウイルス感染症の臨床症状および診断 clinical presentation and diagnosis of dengue virus infections
5. 黄熱 yellow fever

English Journal

Dengue: a newly emerging viral infection in Andaman and Nicobar Islands, India.

Chaaithanya IK, Bhattacharya D, Muruganandam N, Thamizhmani R, Babu BV, Sundaram SG, Matta M, Singh SS, Vijayachari P.SourceRegional Medical Research Centre (ICMR), Port Blair, Andaman and Nicobar Islands, India.
Epidemiology and infection.Epidemiol Infect.2012 Oct;140(10):1920-4. Epub 2011 Dec 8.
SUMMARY Prior to 2009 dengue fever had not been reported in the Andaman and Nicobar archipelago. In 2009, a few patients with dengue fever-like illness were reported, some of whom tested positive for dengue antibodies. In 2010, 516 suspected cases were reported, including some with dengue
PMID 22152648

Fulminant intravascular lymphomatosis mimicking acute haemorrhagic leukoencephalopathy.

Marino D, Sicurelli F, Cerase A, Tripodi S, Cintorino M, Lazzi S, Federico A.SourceDepartment of Neurological, Neurosurgical and Behavioural Sciences, University of Siena, Italy.
Journal of the neurological sciences.J Neurol Sci.2012 Sep 15;320(1-2):141-4. Epub 2012 Jun 21.
BACKGROUND: Intravascular lymphomatosis (IVL) is a rare non-Hodgkin's lymphoma, usually of B cell lineage, characterized by massive angiotropic growth. The clinical presentation of IVL may include changes in mental status, non-localizing neurological deficits, seizures, fever of unknown origin and s
PMID 22726354

Japanese Journal

デング出血熱とその媒介蚊、ワクチンに関するモデル構築 (第4回生物数学の理論とその応用)

長尾吉郎,坂本亘
数理解析研究所講究録 1597, 40-49, 2008-05-00
NAID 110006648489

MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause pearmeabilty change, possibly through reduced tight junctions of vascular endothelium cells